Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563023 | 0.92 | NPC1L1 (0.64) | NPC1L1BDKRB2 | |
| SCHEMBL318756 | 0.91 | NPC1L1 (0.61) | NPC1L1 | |
| SCHEMBL10248363 | 0.90 | NPC1L1 (0.58) | NPC1L1BDKRB2 | |
| SCHEMBL318723 | 0.90 | NPC1L1 (0.59) | NPC1L1BDKRB2 | |
| SCHEMBL318333 | 0.86 | NPC1L1 (0.56) | NPC1L1BDKRB2 | |
| SCHEMBL8811610 | 0.86 | NPC1L1 (0.57) | NPC1L1 | |
| SCHEMBL318225 | 0.85 | NPC1L1 (0.59) | NPC1L1BDKRB2 | |
| SCHEMBL319383 | 0.85 | NPC1L1 (0.55) | NPC1L1 | |
| SCHEMBL319932 | 0.85 | NPC1L1 (0.55) | NPC1L1 | |
| SCHEMBL12490745 | 0.84 | NPC1L1 (0.59) | NPC1L1BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8691836-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2014-04-08 | — | — | US | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | NPC1L1 2825/4885BDKRB2 31/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | NPC1L1 2825/4885BDKRB2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.